Sign In
Buy KRON
$0.88
+0 (+0%)
At Close: Sep 19, 2025
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
08:00am, Tuesday, 26'th Jan 2021
SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
MYC amplification found in approximately 30% of solid tumors
Kronos Bio Announces Participation in Upcoming Investor Conferences
08:00am, Monday, 23'rd Nov 2020
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
08:00am, Wednesday, 18'th Nov 2020
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia
Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference
08:00am, Wednesday, 11'th Nov 2020
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
